University of Pisa, Department of Pharmacy, Via Bonanno 6, 56126 Pisa, Italy.
University of Florence, NEUROFARBA Dept., Sezione di Scienze Farmaceutiche e Nutraceutiche, Via Ugo Schiff 6, 50019 Sesto Fiorentino (Florence), Italy.
Bioorg Chem. 2020 Jul;100:103896. doi: 10.1016/j.bioorg.2020.103896. Epub 2020 May 4.
N-aryl-N'-ureido-O-sulfamates (AUSs) were recently reported as new class of Carbonic Anhydrase Inhibitors (CAIs), endowed of high potency and selectivity against hCA VII and XII. In this work, we extended the investigational study on this new class of CAIs profiling them against the mitochondrial CA isoforms hCA VA and VB. The results revealed a very interesting selectivity profile, with dramatic selectivity against hCA VB over the VA isoform observed for all the analyzed compounds 2-22. On derivative 15, selected as one of the most promising among the series, molecular modeling studies were conducted, highlighting the importance of small residue substitution between the two isoforms in substantially changing the tail orientation and interaction with the enzymes.
N-芳基-N'-脲基-O-磺胺酯(AUS)最近被报道为新型碳酸酐酶抑制剂(CAIs),对 hCA VII 和 XII 具有高活性和选择性。在这项工作中,我们对这一新类 CAIs 进行了扩展研究,对其进行了线粒体 CA 同工型 hCA VA 和 VB 的分析。结果显示出非常有趣的选择性特征,所有分析的化合物 2-22 对 hCA VB 的选择性明显高于 hCA VA。对衍生物 15 进行了研究,该化合物被选为该系列中最有前途的化合物之一,进行了分子建模研究,突出了两个同工型之间小残基取代的重要性,这实质上改变了尾部的取向和与酶的相互作用。